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AbstrACt
Objective In the setting of reperfused ST-elevation 
myocardial infarction (STEMI), increased production of 
reactive oxygen species (ROS) contributes to reperfusion 
injury. Among ROS, hydrogen peroxide (H
2O2) showed 
toxic effects on human cardiomyocytes and may induce 
microcirculatory impairment. Glutathione (GSH) is a water-
soluble tripeptide with a potent oxidant scavenging activity. 
We hypothesised that the infusion of GSH before acute 
reoxygenation might counteract the deleterious effects of 
increased H
2O2 generation on myocardium.
Methods Fifty consecutive patients with STEMI, 
scheduled to undergo primary angioplasty, were randomly 
assigned, before intervention, to receive an infusion of 
GSH (2500 mg/25 mL over 10 min), followed by drug 
administration at the same doses at 24, 48 and 72 hours 
elapsing time or placebo. Peripheral blood samples were 
obtained before and at the end of the procedure, as well 
as after 5 days. H
2O2 production, 8-iso-prostaglandin F2α 
(PGF2α) formation, H2O2 breakdown activity (HBA) and 
nitric oxide (NO) bioavailability were determined. Serum 
cardiactroponin T (cTpT) was measured at admission and 
up to 5 days.
results Following acute reperfusion, a significant 
reduction of H
2O2 production (p=0.0015) and 8-iso-PGF2α 
levels (p=0.0003), as well as a significant increase in HBA 
(p<0.0001)and NO bioavailability (p=0.035), was found 
in the GSH group as compared with placebo. In treated 
patients, attenuated production of H
2O2 persisted up to 
5 days from the index procedure (p=0.009) and these 
changes was linked to those of the cTpT levels (r=0.41, 
p=0.023).
Conclusion The prophylactic and prolonged infusion of 
GSH seems to determine a rapid onset and persistent 
blunting of H
2O2 generation improving myocardial cell 
survival. Nevertheless, a larger trial, adequately powered 
for evaluation of clinical endpoints, is ongoing to confirm 
the current finding.
trial registration number EUDRACT 2014-00448625; 
Pre-results.
IntrOduCtIOn
It is well known that reactive oxygen species 
(ROS) are produced at an accelerated rate in 
tissues subjected to reperfusion and that the 
accumulation of ROS contributes to reperfu-
sion injury during reintroduction of molec-
ular oxygen to the ischaemic environment.1 2 
In the setting of ST-elevation myocardial 
infarction (STEMI), ROS-induced myocardial 
cell death occurs in the first few minutes of 
the acute reoxygenation3 and may continue 
for weeks to months by the activation of apop-
tosis and autophagy processes.4 5 ROS gener-
ation also contributes to structural capillary 
damage and endothelial dysfunction, which 
hinder the achievement of an optimal perfu-
sion grade at microcirculatory level.6 7 Over 
the time, this may result in adverse left 
ventricular (LV) remodelling and worse LV 
function.8–10
strengths and limitations of this study
 ► In patients who suffer from ST-elevation myocardial 
infarction (STEMI), acute reoxygenation of ischaemic 
myocardium can induce additional myocardial cell 
injury mainly driven by heightened oxidative status.
 ► Reactive oxygen species generation further contrib-
utes to damage myocardium by limiting bioavailabil-
ity of nitric oxide (NO) at microcirculatory level.
 ► This pilot study demonstrates that in the setting of 
STEMI reperfusion, the rapid onset and prolonged 
antioxidant (scavenging) activity obtained by the in-
fusion of glutathione (GSH) protects the myocardium.
 ► This study is limited by the lack of clinical endpoints 
and the small sample size. Moreover, qualitative 
assessment of GSH-induced improvement of myo-
cardial reperfusion indexes might only represent the 
effect of a preserved microcirculatory responsive-
ness to vasoactive substances (ie, NO) but unable to 
limit the expansion of myocardial cell damage.
by copyright.
 o
n
 Septem
ber 12, 2019 at Univ of Rom
e La Sapienza. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025884 on 8 August 2019. Downloaded from 
2 Tanzilli G, et al. BMJ Open 2019;9:e025884. doi:10.1136/bmjopen-2018-025884
Open access 
Among ROS, hydrogen peroxide (H2O2) is produced by 
many enzymes, including, for example, xanthine oxidase, 
lipoxygenase and, in particular, Nicotinamide Adenine 
Dinucleotide Phosphate (NADPH) oxidase.11 H2O2 shows 
an important role in ischaemia/reperfusion damage. In 
particular, the exposure of cultured human cardiomyo-
cytes to H2O2 has determined rapid onset and progressive 
oxidative cell death.12 Moreover, H2O2 influences platelet 
activation and promotes vascular dysfunction through 
thromboxane A2 and isoprostanes formation, which are 
vasoconstrictors and powerful aggregating molecules 
derived from lipid peroxidation of esterified unsaturated 
fatty acids.13–15
Human possesses numerous enzymatic and non-en-
zymatic antioxidant systems. Among enzymatic systems, 
glutathione peroxidase (GPx) plays an important role to 
prevent potentially deleterious effects of H2O2.
16 Thus, the 
reduced plasma level of glutathione (GSH), a water-sol-
uble tripeptide with a potent oxidant scavenging activity 
and fundamental substrate for GPx activity, could have 
a key role in promoting myocardial and endothelial cell 
damage.17 In fact, a decrease in myocardial GSH content 
has been observed during ischaemia and reperfusion of 
the ischaemic myocardium.18
Despite robust evidences regarding the role of ROS in 
reperfusion injury, currently, in clinical practice, there 
are no treatments aimed at preventing ROS generation.
Preclinical study of ischaemia/reperfusion demon-
strated that timely application of GSH provides better 
cardioprotection at higher doses.19 Our hypothesis is 
that the use of GSH might counteract deleterious effect 
of augmented oxidant activity during reperfusion of 
STEMI.20 Currently, a GSH solution is available for intra-
venous usage to reduce side effects of chemotherapy 
treatment for cancer with a tolerable safety profile, 
however, it has never been tested in the setting of patients 
with STEMI.
Therefore, we performed a pilot study to explore 
whether a short-term intravenous GSH administration, 
just before and after a primary percutaneous coronary 
intervention (p-PCI) inpatients with STEMI , was able to 
reduce oxidative stress and antioxidant status markers, 
resulting in a reduction of the myocardial damage.
MethOds
study design
GSH2014 is a multicentre, no profit, randomised, 
double-blind, prospective and placebo-controlled trial. 
The Department of Heart and Great Vessel ‘A. Reale’, 
Sapienza University of Rome, Italy was the coordinator 
centre and designed the protocol (see online supple-
mentary file). Two other centres, ‘Santa Maria’ Terni 
Hospital and ‘San Giovanni Evangelista’ Tivoli Hospital, 
both in Italy, were involved in the study as recruiting 
site.
Patient and public involvement
Patients and/or public were not involved in the different 
stages of the study (including the design and the recruit-
ment phase). However, we intend to disseminate the 
main results to trial participants and will seek patient and 
public involvement in the development of an appropriate 
method of dissemination.
study population and protocol
Between March and August 2017, 157 consecutive 
patients with STEMI , age >18 years, both sexes, referred 
to the three enrolling centres for p-PCI were screened to 
enter in the study. Inclusion criteria were: typical chest 
pain lasting more than 30 min with pain onset <12 hours, 
ST segment elevation >0.2 mV in at least two contiguous 
leads in the initial ECG, successful p-PCI (residual coro-
nary stenosis <20%) and blood sampling for biochemical 
determinations collected prior to p-PCI.
Exclusion criteria were: symptoms duration >12 hours 
(n=15), rescue PCI (n=16), cardiogenic shock (n=3), 
left main disease (n=3), evidence of coronary collateral 
vessels (Rentrop score of 2 or 3 for the area at risk) (n=5), 
prior myocardial infarction (n=7), estimated glomerular 
filtration rate less than 30 mL/min (n=13), acute infec-
tion (n=2), treatment with systemic corticosteroids (n=4) 
or oral anticoagulants (n=7), malignancy (n=3), in-stent 
Figure 1 CONSORT flow chart. GSH, glutathione; 
MI, myocardial infarction; PCI, percutaneous coronary 
intervention. CONSORT,  Consolidated Standards of 
Reporting Trials. 
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thrombosis (n=3), lack of consent to participate (n=18). 
Additionally, eight patients were ineligible because no 
blood samples were collected before the start of the 
procedure. Finally, a total of 50 patients were enrolled 
(see figure 1). The present analysis reported the results 
of the interim analysis (preplanned in the protocol) on 
the acute effect of GSH infusion on markers of oxidative 
stress.
After percutaneous access was obtained, an intrave-
nous bolus of 5000 U of unfractionated heparin was 
administered, with sufficient supplements (if necessary) 
to maintain an activated clotting time of ≥250 s during 
interventions.
After baseline collection of peripheral blood samples, 
patients were randomised to an intravenous infusion 
of GSH (2500 mg/25 mL of glutathione sodium salt, 
Biomedica Foscama Group, Rome, Italy) or placebo 
(saline solution) over 10 min before p-PCI. The two solu-
tions appeared identical in size and colour to ensure 
blinding. Study participants, investigators and the labo-
ratory staff remained blinded until the statistical analysis 
was performed by an independent researcher who was 
not involved in the study.
Patients underwent p-PCI according to the standard 
protocols. The use of thrombus aspiration, glycopro-
tein IIb/IIIa inhibition was left to the discretion of the 
treating physician. Multivessel PCI was performed in a 
staged fashion (7–10 days from index procedure).
All patients had drug-eluting stents implanted in treated 
vessels. After interventions, GSH was infused at the same 
doses at 24, 48 and 72 hours elapsing time. Further blood 
samples were obtained at the end of the procedure and 5 
days from index procedure.
After 60’−90’, a postprocedural 12 leads ECG for ST 
measurement were performed.
Corrected Thrombolysis in Myocardial Infarction 
(TIMI) frame count (cTFC) and TIMI myocardial perfu-
sion grade (TMPG) were assessed after p-PCI as previously 
described.21 An external Core Lab processed the data 
(G.P and G.P: independent cardiologists). Digital angio-
grams were analysed off-line with the use of an automated 
edge detection system (Cardiovascular Medical System, 
MEDIS Imaging Systems, Leiden, the Netherlands).
randomisation and blinding
An individual was not involved in the study assigned 
codes (using a computer-generated random sequence) to 
the study treatment with a random allocation of patients 
to an intravenous infusion of GSH (2500 mg/25 mL over 
10 min) or placebo (saline solution) before p-PCI. The 
interventional cardiologists who performed p-PCI, those 
who analysed digital angiograms and the laboratory tech-
nicians, were unaware of study treatment allocation.
Primary endpoint
The primary endpoint was the change on oxidative stress 
markers levels after 2 hours from p-PCI in patients treated 
with GSH as compared with placebo.
secondary endpoints
The secondary endpoints included the assessment of: 
(1) changes of oxidative stress markers levels after 5 days 
from the p-PCI in patients received GSH or placebo; (2) 
changes in serum cardiac troponin T (cTpT), biochem-
ical markers of myocardial cell damage, in patients 
Table 1 Clinical characteristics of the study population
Variables
GSH group
(n=25)
Placebo 
group (n=25) P value
Age (y, mean±SD) 66±10.7 66.9±9.1 0.74
Male, n (%) 15 (60) 13 (52) 0.98
Body mass 
index* (mean+SD)
26.9±3.9 20±3.8 0.38
Killip class ≥3, n (%) 2 (8) 0 (0) 0.47
Diabetes mellitus, n (%) 5 (20) 5 (20) 1
Hypertension, n (%) 14 (56) 17 (68) 0.56
Dyslipidaemia, n (%) 11 (44) 13 (52) 0.77
Statin use, n (%) 8 (32) 8 (32) 1
Smokers, n (%) 17 (68) 13 (52) 0.38
*The body mass index is the weight in kilograms divided by the 
square of the height in metres.
Table 2 Angiographic parameters
Variables
GSH group
(n=25)
Placebo 
group
(n=25) P value
Ischaemia time# (min; 
mean±SD)
286±88 270±96 0.85
Thrombus burden ≥3, 
n (%)
12 (48) 11 (44) 0.77
Thrombus aspiration, 
n (%)
13 (52) 12 (48) 0.87
GP IIb/IIIa inhibitors, 
n (%)
2 (8) 3 (12) 0.63
 MVD, n (%) 13 (52) 11 (44) 0.77
2 vessels, 8 (32) 5 (20) 
3 vessels, 5 (20) 6 (24) 
Staged PCI, n (%) 9 (36) 5 (20) 0.89
IRA 
  LAD, n (%) 10 (40) 9 (36) 0.77
  LCx, n (%) 5 (20) 6 (24) 0.73
  RCA , n (%) 10 (40) 10 (40) 1
Ischaemia time was defined as the timing between symptom onset 
and balloon inflation. 
GSH, glutathione; GP, general practitioner; IRA, infarct related 
coronary artery; LAD, left anterior descending coronary artery; 
LCx, left circumflex coronary artery; PCI, percutaneous coronary 
intervention; RCA, Right coronary artery. 
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received GSH or placebo before and after 5 days from the 
procedure.
Peripheral blood samples
Blood samples were drawn from antecubital vein, before 
the start of procedure and after stent deployment in all 
patients and then collected into tubes without anticoag-
ulant or with 3.8% sodium citrate, lithium heparin and 
EDTA and centrifuged at 300×g for 10 min to obtain 
supernatant. All plasma and serum aliquots were stored 
at −80°C in appropriate cuvettes until assayed.
Markers of oxidative stress and antioxidant system (ie, 
H2O2, H2O2 breakdown activity (HBA) and 8-iso-prosta-
glandin F2α (PGF2α)) were analysed in serum samples 
collected before p-PCI, 2 hours and 5 days after p-PCI. 
Due to the chemical properties of the oxidative stress 
markers, to avoid a long-time storage of blood samples 
and guarantee the laboratory test quality the analyses 
were performed within 6 months from the collection.
Serum cTpT was measured at admission, before the 
procedure, 6 and 12 hours after reperfusion, and there-
after once a day up to 5 days. Serum cTpT levels were 
measured using the ELISA Kit (Elabsciences).
h2O2 production
The H2O2 was evaluated by a Colorimetric Detection Kit 
(Assays, Ann Arbor, Michigan, USA) and expressed as 
μM. Intra-assay and interassay coefficients of variation 
were 2.1% and 3.7%, respectively.
determination of % hbA in peripheral serum
The evaluation of the ability to detoxify H2O2 was assessed 
by the analysis of the HBA in serum with the HBA assay kit 
(Aurogene, Rome, Italy, code HPSA-50). The per cent of 
HBA was calculated according to the following formula: 
% of HBA = [(Ac-As)/Ac] × 100, where Ac is the absor-
bance of H2O2 1.4 mg/mL and As is the absorbance in the 
presence of the serum sample.
serum nitric oxide bioavailability
A colorimetric assay kit (Cell Biolabs, San Diego, Cali-
fornia, USA) was used to determine NO bioavailability by 
measurement of the nitric oxide (NO) metabolites nitrite 
and nitrate in the serum. Intra-assay and interassay coeffi-
cients of variation were 2.9% and 1.7%, respectively.
serum 8-iso-PGF2α formation
Concentration of 8-iso-PGF2α in serum was measured 
by validated enzyme immunoassay method (DRG Inter-
national, Springfield, New Jersey, USA). Intra-assay and 
interassay coefficients of variation were 5.8% and 5.0%, 
respectively. Values were expressed as pmol/L.
Myocardial function
After 120 min and 5 days from the intervention, LV end-di-
astolic volume (LVEDV), LV end-systolic volume (LVESV) 
and LV ejection fraction (LVEF) were calculated by the 
biplane Simpson’s rule, as recommended by the Amer-
ican Society of Echocardiography. The mean values of 
three measurements were used for statistical evaluation.
sample size calculation
For the present preliminary analysis, the sample size 
calculation was estimated considering previous data avail-
able for 8-iso-PGF2α levels.22 A sample size of 25 patients 
undergoing GSH infusion provided an intervention study 
with 80% power to detect a 20% reduction in plasmatic 
8-iso-PGF2-α levels measured at the end of successfully 
reperfusion with respect to the placebo group. We also 
assumed a 25% SD in each group.
statistical analysis
Categorical variables were reported as counts 
(percentage) and continuous variables as means±SD. We 
tested the independence of categorical variables by χ2 test 
and the normal distribution of continuous variables by 
Kolmogorov-Smirnov test. We used Student paired and 
Table 3 Biochemical data
Variable
Baseline Reperfusion 2 hours Follow-up (5 days)
GSH Placebo P value GSH Placebo P value GSH Placebo P value
H2O2
µM, mean±SD
Δ
40.6±8.4 43.6±11.6 0.305 28.4±12 42.8±14.1 0.0003 24±7 39.5±17.3 0.0001
−12.1±15.2 −0.7±17.9 0.03 −16.6±11.0 −4.1±20.14 0.009
8-iso-PGF2α 
pmol/L, 
mean±SD
Δ
214.6±81.1 211.9±92.1 0.91 163.6±44.7 217.6±51.6 0.0003 159.9±34.2 213.1±50.9 0.0001
−50.9±92.9 −3.3±1.29 0.02 −54.6±62.1 −1.2±115.7 0.02
HBA
%, mean±SD
Δ
43.6±7.4 43.4±11.9 0.94 57.9±8.6 43.9±8.7 0.0001 62.9±10.5 45.2±13.0 0.0001
+14.9±5.5 +0.4±14.9 0.0004 +19.4±10.2 +1.8±17.1 0.0001
NO
µM, mean±SD
Δ
16.3±5.7 16.5±4.7 0.89 27.7±7.2 22.4±10 0.0356 35.5±8.1 23.5±15.5 0.0013
+11.4±6.8 +5.8±10.5 0.05 +19.2±9.7 +7.0±14.7 0.002
8-iso-PGF2α, 8-iso-prostaglandin-F2α; GSH, glutathione; H2O2, hydrogen peroxide; HBA, H2O2 break-down activity; NO, nitric oxide.
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unpaired t-test, repeated measure analysis of variance 
(ANOVA) and Pearson product-moment correlation anal-
ysis to evaluate normally distributed continuous variables. 
Appropriate non-parametric tests (Mann-Whitney U test, 
Wilcoxon signed-rank test and Spearman rank correla-
tion test) were employed for all the other variables. As 
an overall non-parametric ANOVA, the Friedman test 
for the analysis of intragroup variations was used. In 
cases of significance, we compared pair related samples 
using the Wilcoxon signed-rank test. The intergroup 
analysis was performed with the non-parametric Mann-
Whitney U test. Only two-tailed probabilities were used 
for testing statistical significance. Probability values <0.05 
were regarded as statistically significant. All calculations 
were made with the computer program STATISTICA V.7 
(StatSoft).
results
Twenty-five patients randomly received GSH and 25 
placebo. All patients completed the phases of the study 
(figure 1). All patients had a TIMI flow grade equal to 0 or 
1 requiring percutaneous treatment. Clinical and angio-
graphic characteristics of patients are shown in tables 1 
and 2. The baseline characteristics were well balanced 
between the two groups. In both groups, neither side 
effects during the infusion, nor adverse events during the 
short observation period were recorded.
Oxidative stress, antioxidant status and vascular 
function in peripheral samples. Biochemical data are 
summarised in table 3. Baseline H2O2 and 8-iso-PGF2α 
levels were similar between treated patients and controls. 
After PCI, a significant reduction of H2O2 production 
and 8-iso-PGF2α levels was observed in GSH group as 
compared with the controls (figure 2A,B). Moreover, a 
significant increase in HBA and NO bioavailability was 
observed (figure 2C,D).
At the 5 days from index procedure, a persistent signif-
icant reduction of H2O2 production and a sustained 
increase in HBA and NO bioavailability was observed in 
the GSH group as compared with controls (figure 2A–D).
serological markers of myocardial injury
Baseline cTpT mean values were similar between GSH 
and placebo groups (176.0±20.9 pg/mL vs 165.4±20.9 pg/
mL, p=0.079). At 6 hours, no changes in cTpT values 
were found in GSH-treated patients (172.1±27.7 pg/mL 
vs baseline, p=0.065). At 12 hours and 5 days after p-PCI, 
GSH-treated patients showed a progressive decrease of 
cTpT levels (170.0±44.7 pg/mL and 137.9±23.7 pg/mL; 
−21±23.1%, p=0.009 vs baseline). Differently, a signif-
icant increase and persistence of high values of cTpT 
were observed in placebo group (T6, 169.9±16.3 pg/
mL, T12, 183.0±34.8 pg/mL and T5d, 181.9±18.0 pg/
mL; +12.4%±23.1%, p=0.029 vs baseline) (figure 3A). A 
Figure 2 H2O2 production (A), 8-iso-PGF2α formation 
(B), H2O2 breakdown activity (HBA) (C) and NO 
bioavailability (D) at baseline, after 2 hours (T2h) and at 
the 5 days (T5d) from the PCI in patients received GSH 
(n=25, dashed line) or placebo (n=25, continuous line). 
Data are expressed as mean±SEM (*P<0.05, **P<0.01, 
***P<0.001). GSH, glutathione; H2O2, hydrogen peroxide; 
NO, nitric oxide; PCI, percutaneous coronary intervention; 
PGF2α, prostaglandin F2α. 
Figure 3 cTpT levels (A) at baseline, after 6 hours (T6h), 
12 hours (T12h) and at the 5 days (T5d) from the PCI in 
patients received GSH (n=25, dashed line) or placebo 
(n=25, continuous line). Data are expressed as mean±SEM 
(*P<0.05 vs T0, ***P<0.0001 vs T0, $P<0.05 between groups). 
Linear correlation between % Δ cTpT and % Δ H2O2 in GSH-
treated group (B). cTpT, cardiac troponin T; H2O2, hydrogen 
peroxide; GSH, glutathione; PCI, percutaneous coronary 
intervention. 
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modest correlation between percentage changes of H2O2 
and cTpT levels from baseline to 5 days was found in 
the treated group (figure 3B).
Myocardial reperfusion indexes
Postprocedural cTFC values did not show a statistically 
significant reduction between treated and control groups 
(20.7±7.3 vs 23.4±5.1, p=0.156). Interestingly, six patients 
(24%) in the placebo group and 15 (60%) patients in 
GSH group reached lower risk (≤20 frames/s) cTFC class 
(p=0.019). After PCI, TMPG ≥2 was assessed in 21 patients 
(84%) and 14 patients (56%) of the GSH and placebo 
groups, respectively (p=0.064). Of note, 11 patients 
(44%) of the GSH group only had TMPG=3 (p=0.0002 vs 
controls). Postreperfusion cTFC values showed a signif-
icant correlation with changes of 8-iso-PGF2α (R=0.55, 
p=0.012) levels from baseline.
Myocardial function
Myocardial function was not different between groups 
after either baseline or at discharge. There was no signif-
icant difference between groups regarding LVEF, LVEDV 
or LVESV at any time point (table 4).
dIsCussIOn
This pilot study demonstrates that in the setting of STEMI 
reperfusion the rapid onset and prolonged antioxi-
dant (scavenging) activity obtained by infusion of GSH 
before and after primary PCI reduces the oxidative stress 
markers. The improvement of the antioxidant status 
resulted in a significant decrease of cardiac troponin, 
marker of myocardial damage.
Data from experimental and clinical studies suggest 
that following reperfusion myocardial cells death largely 
contributes to the final infarct size.23 24 On the other 
hand, the extent of damaged myocardium is the most 
important predictor of adverse ventricular remodelling 
and it is linearly dependent on the amount of myocardial 
salvage by and after reperfusion. Thus, attenuation of 
prooxidant state is an important goal in cardioprotective 
interventions.25 Noteworthy, the serum of GSH-treated 
patients showed a greater capacity to detoxify H2O2 eval-
uated by the HBA, an assay that measure the percentage 
of H2O2 neutralised into the samples.
26 We found an early 
and considerable increase of HBA, with positive effects 
on myocardial cell survival, assessed by cTpT.
Current evidences demonstrate that oxidant envi-
ronment promotes cardiomyocyte death in the first few 
minutes of reflow suggesting the existence of a tight 
window of effective cardioprotection.27 28 Therefore, 
ROS-induced injury may continue for weeks to months as 
a result of activation of programmed cell death. Our data 
have shown a persistent heightened oxidative status along 
with decreased scavenging activity in untreated patients. 
This behaviour makes the duration of pharmacological 
interventions a central point of cardioprotection strat-
egies. In the present study, GSH infusion, starting just 
before reperfusion with subsequent administration up 
to 3 days after, promoted early and sustained increase of 
serum HBA with attenuated production of H2O2, which 
was highly related to progressive significant reduction of 
serological signs of myocardial injury. In addition, our 
data show a progressive significant decrease of serum 
cTpT release during the 5 days of reperfusion in the 
GSH-treated patients compared with the control group 
resulting in a 21% reduction of myocardial damage. 
Despite that, in our population, the systolic function was 
not different between groups after reperfusion, although 
a trend towards reduced LVEDV was observed in treated 
patients. A possible explanation relies on the fact that 
inside the area at risk variable amount of hibernated 
and stunned myocardium may coexist, thus affecting the 
prompt recovery of contractility after reperfusion.29
Cells have a number of mechanisms for dealing with 
the toxic effects of oxygen. One of the most important 
is connected with the widely distributed tripeptide thiol 
GSH.16 30 In particular, the GSH redox cycle is a more 
efficient antioxidant protective mechanism of the heart, 
which acts by maintaining thiol groups of enzymes and 
other proteins in their reduced state thus preventing cell 
membrane lipid peroxidation and limiting cardiomyo-
cytes loss.31 Furthermore, in our study, a close relation 
between reduced myocardial reperfusion and increased 
of 8-iso-PGF2α serum levels has been observed, suggesting 
that oxidative unbalance may be involved in microcircula-
tion functional damage. As previously reported, impaired 
tissue-level perfusion develops within minutes of estab-
lished acute revascularisation of ischaemic areas32 and 
persists for at least 1 week.33 In this context, there is robust 
evidence that ROS-mediated isoprostanes production 
contributes importantly to the postreperfusion microvas-
cular impairment.22 34 Current findings implement this 
observation by demonstrating a sustained production 
of isoprostanes up to 5 days after reperfusion thereby 
suggesting their contributory role in the pathogenesis and 
persistence of microvascular dysfunction that may affect 
Table 4 Left ventricular echocardiographic 
(ECHO) parameters at baseline and at follow-up
ECHO parameters
Placebo
(n=25)
GSH
(n=25) P value
Baseline 
  LVEDV (mL/m2) 121.3±17.2 124.4±22.3 0.44
  LVESV (mL/m2) 65.4±11.3 66.3±13.2 0.91
  LVEF (%) 47.5±4.9 46.9±4.8 0.42
Follow-up
  LVEDV (mL/m2) 118.1±17.8 113.2±14.1 0.42
  LVESV (mL/m2) 60.9±10.7 58.8±12.5 0.91
  LVEF (%) 49.1±3.2 49.8±3.7 0.42
GSH, glutathione; LVESV, left ventricular end-systolic volume; 
LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular 
ejection fraction.
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myocardial cell survival. The infusion of GSH before and 
24, 48, 72 hours after p-PCI reduced isoprostanes serum 
levels and their reduction was linked to improvement of 
myocardial reperfusion indexes. Moreover, the increase 
in extracellular peroxide oxidants may reduce bioavail-
ability of NO that is thought to contribute to promoting 
platelet hyperactivity and vasoconstriction.13 In our study, 
GSH supplementation seems to have a role in preserving 
NO bioavailability and its vasodilator capacity at microcir-
culatory level.
the strengths and limitations of the study
The positive effects on reperfusion indexes and on 
biochemical signs of myocardial necrosis suggest the 
value of prophylactic and prolonged GSH administra-
tion in preventing reperfusion injury. Thus, in patients 
undergoing p-PCI the infusion of a powerful antioxidant 
scavenger, such as GSH, may be useful to improve micro-
circulatory perfusion in order to further blunt the injury 
of myocardial cells.
some limitations deserve to be discussed
The small sample size of the study and the lack of morpho-
logical  assessment of both infarct size and microvascular 
obstruction extent between the two groups, actually, limit 
the clinical application of these findings. Within a defined 
area at risk, the manifestations of ischaemia-reperfusion 
vascular injury go from reversible functional impairments 
to irreversible structural damage and contribute to final 
amount of infarct myocardium. In absence of morpho-
logical imaging, the qualitative evaluation of GSH-in-
duced improvement of myocardial reperfusion indexes, 
as assessed in our study, might only represent the effect 
of a preserved microcirculatory responsiveness to vasoac-
tive substances (ie, NO) but unable to limit the expansion 
of myocardial cell damage. Indeed, other mechanisms, 
such as interstitial oedema and inflammatory reaction, 
which induce a sustained impairment of microvascular 
perfusion, may primarily act to increase the amount of 
irreversible injured myocardium thus promoting adverse 
ventricular remodelling.
In conclusion, in this pilot study, we have shown that a 
short-term prophylactic GSH infusion mitigates the nega-
tive effects of the excessive and persistent H2O2 formation 
on myocardial cells. The findings of the present study 
require to be confirmed through an adequately powered 
STEMI population. A larger trial with a prolonged 
follow-up for evaluation of clinical endpoints is needed 
to confirm the role of GSH administration as cardiopro-
tective therapy.
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